Chip stocks fall with Nvidia after data center rev disappointment
James George Chopas, Vice President and Chief Accounting Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a biopharmaceutical company with a market capitalization of $3.1 billion, recently sold a portion of his company stock. The transaction comes as the stock trades near its 52-week low, having declined over 55% in the past year. According to a recent SEC filing, Chopas disposed of 183 shares of Apellis common stock on March 17, 2025. The shares were sold at an average price of $24.8237 each, totaling approximately $4,542. Following this transaction, Chopas retains ownership of 47,955 shares of the company’s stock. The sale was conducted to cover tax withholding obligations related to restricted stock units released earlier in the month.
In other recent news, Apellis Pharmaceuticals reported fourth-quarter revenue of $212.5 million, surpassing the consensus estimate of $192.9 million and marking a 45% increase from the same quarter last year. The company also posted adjusted earnings per share of -$0.29, beating analyst expectations of -$0.37. SYFOVRE, Apellis’s treatment for geographic atrophy, generated $167.8 million in U.S. net product revenue, while EMPAVELI contributed $23.4 million. Despite these strong financial results, Apellis’s shares fell following the earnings release.
Analysts from Raymond (NSE:RYMD) James, Stifel, and TD Cowen have maintained positive ratings on Apellis, although Stifel and Raymond James have adjusted their price targets to $60 and $75, respectively. Apellis is focusing on expanding its market presence with the anticipated launch of new products and ongoing trials, including a supplemental New Drug Application for pegcetacoplan. The company remains optimistic about its cash reserves of $411 million, which it believes will support operations until it reaches profitability. Apellis plans to initiate two Phase 3 trials of EMPAVELI in the second half of 2025, targeting Focal Segmental Glomerulosclerosis and Delayed Graft Function.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.